CRISPR Therapeutics to Participate in Upcoming Investor Conferences
May 29 2024 - 8:00AM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company
focused on creating transformative gene-based medicines for serious
diseases, today announced that members of its senior management
team are scheduled to participate in the following investor
conferences in June.
Jefferies Healthcare
ConferenceDate: Wednesday, June 5, 2024Time: 10:00 a.m.
ET
Goldman Sach’s 45th Annual Global
Healthcare ConferenceDate: Tuesday, June 11, 2024Time:
9:20 a.m. ET
A live webcast will be available on the "Events
& Presentations" page in the Investors section of the Company's
website at https://crisprtx.gcs-web.com/events. A replay of the
webcasts will be archived on the Company's website for 14 days
following the presentation.
About CRISPR TherapeuticsSince
its inception over a decade ago, CRISPR Therapeutics has
transformed from a research-stage company advancing programs in the
field of gene editing, to a company that recently celebrated the
historic approval of the first-ever CRISPR-based therapy and has a
diverse portfolio of product candidates across a broad range of
disease areas including hemoglobinopathies, oncology, regenerative
medicine, cardiovascular, autoimmune, and rare diseases. CRISPR
Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited
therapy into the clinic in 2018 to investigate the treatment of
sickle cell disease or transfusion-dependent beta thalassemia, and
beginning in late 2023, CASGEVY™ (exagamglogene autotemcel) was
approved in some countries to treat eligible patients with either
of those conditions. The Nobel Prize-winning CRISPR science has
revolutionized biomedical research and represents a powerful,
clinically validated approach with the potential to create a new
class of potentially transformative medicines. To accelerate and
expand its efforts, CRISPR Therapeutics has established strategic
partnerships with leading companies including Bayer and Vertex
Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug,
Switzerland, with its wholly-owned U.S. subsidiary, CRISPR
Therapeutics, Inc., and R&D operations based in Boston,
Massachusetts and San Francisco, California, and business offices
in London, United Kingdom. To learn more, visit
www.crisprtx.com.
Investor Contact:Susan
Kim+1-617-307-7503susan.kim@crisprtx.com
Media Contact:Rachel Eides
+1-617-315-4493rachel.eides@crisprtx.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Jul 2024 to Aug 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Aug 2023 to Aug 2024